Overview

C-Reveal Therapeutics is developing proprietary small molecule inhibitors of an immunomodulatory target identified and validated in Mark Cobbold's lab at Harvard/MGH. These inhibitors will disable a key novel tumor immune cloaking mechanism thus exposing the tumors to endogenous immune responses. C-Reveal’s drugs will be applicable to a broad spectrum of cancers and potentiate other cancer therapies such as checkpoint inhibitors, cancer vaccination, T Cell therapies and even traditional chemotherapy treatments.